MoonLake Investors Urged to Seek Lead Role in Securities Suit as Dec. 15 Deadline Nears

Overview

• The putative class action, Peters v. MoonLake Immunotherapeutics (No. 25-cv-08612, S.D.N.Y.), alleges violations of Exchange Act §§10(b) and 20(a) and SEC Rule 10b-5.
• The complaint targets purchases of MLTX between March 10, 2024 and September 29, 2025, with motions to be lead plaintiff due December 15, 2025.
• Filings claim MoonLake misled investors by promoting SLK’s Nanobody design as superior to monoclonal antibodies without a reasonable basis.
• Allegations include that SLK and BIMZELX both target IL-17A/IL-17F and that purported tissue-penetration benefits would not deliver superior clinical efficacy.
• MoonLake’s September 28, 2025 Phase 3 VELA update reported noncompetitive efficacy versus BIMZELX, and the stock fell about 90% to $6.24 the next trading day, prompting multiple firms—including Robbins Geller, Rosen, DJS, Frank R. Cruz, and Faruqi—to solicit class members.